Shares of pharma giant AstraZeneca (NYSE:AZN) rose slightly today -- despite reporting mediocre third quarter earnings. Year-over-year revenue dropped, and sales took a hit after some of the company's high profile drugs lost patent protection this year.
In the following video, health care analysts Max Macaluso and David Williamson discuss these results, AstraZeneca's new CEO, and one of AstraZeneca's potential acquisition targets -- Amarin (NASDAQ:AMRN).
Max Macaluso has no positions in the stocks mentioned above. David Williamson owns shares of Amarin and Pfizer, but he holds no other position in any company mentioned. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.